Scientific Advisory Board

Professor Hans Söderlund, PhD, Chairman

Hans Söderlund is the inventor of TRAC technology and closely involved in the company’s R&D processes. Hans has a strong experience in biotechnology from several international research institutes. Since 1992, Hans has worked in the VTT Technical Research Centre of Finland as a Research Professor and Vice President of Strategic Research. Currently he acts as a senior scientific advisor for VTT and as Chairman of the Board at University of Oulu.

Sir Gregory Winter, member

Sir Gregory Winter is a pioneer in development of therapeutic monoclonal antibodies and protein engineering. Greg is the founder of Cambridge antibody technology (later acquired by Astrazeneca), Domantis (later acquired by GlaxoSmithKline) and Bicycle Therapeutics. Greg is the Deputy Director at the Laboratory of Molecular Biology, Cambridge, and from July 2012 Winter will start as the Master of Trinity College, Cambridge. Greg has won several international prizes, including the Prix Louis Jeantet de Medecine, the King Faisal International Prize for Medicine, the Cancer Research Institute William B. Coley Award and the National Biotechnology Ventures Award.

Frank W Bonner, PhD, member

Frank Bonner is Chief Executive of Stem Cells for Safer Medicines, a Public-Private partnership which is focused upon developing stem cell assays for predictive toxicology. Frank has over 25 years of experience of toxicology and non-clinical drug development, gained in the pharmaceutical, biotechnology and contract research industries and as an independent consultant providing scientific and regulatory advice for drug development. He is a Fellow of the British Toxicology Society, Past President of the Society and has participated on a number of national committees of the Association of the British Pharmaceutical Industry.

Professor Ann-Christine Syvänen, PhD, member

Ann-Christine Syvänen is a Professor in Molecular Medicine at Uppsala University, Sweden. She heads a research group that studies human diseases using modern methods for genomics and epigenetics, often in collaboration with clinical collaborators (www.medsci.uu.se/molmed). Previously working in Finland Ann-Christine performed pioneering work to develop the “minisequencing” primer extension method, which is the reaction principle underlying the major SNP-genotyping methods used today. Ann-Christine Syvänen is also the Director of the SNP&SEQ Technology Platform in Uppsala (www.genotyping.se), which offers SNP genotyping and second generation DNA sequencing services to academic research projects.